Calvo Romero J M
Servicio de Medicina Interna, Hospital Ciudad de Coria, Coria, Cáceres, España.
Rev Clin Esp. 2011 Mar;211(3):142-6. doi: 10.1016/j.rce.2010.12.001. Epub 2011 Mar 2.
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage.
尽管没有禁忌证，但有中风风险的心房颤动（AF）患者并不总是接受维生素K拮抗剂（VKA）抗凝治疗。达比加群是一种口服直接凝血酶抑制剂，在这些患者中已证明具有安全性和有效性，是一种新的选择。达比加群的优点是其反应更可预测，无需凝血监测，且出血频率可能较低。其缺点是成本高、缺乏解毒剂和长期数据、消化不良频率以及每日两次给药。
